MustGrow Biologics Corp. Share Price Canadian Securities Exchange
Equities
MGRO
CA62822A1030
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | +6.74% | -28.57% |
23/04 | MustGrow Biologics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
22/01 | MustGrow Biologics Corp.(TSXV:MGRO) dropped from S&P/TSX Venture Composite Index | CI |
Sales 2024 * | 280K 205K 17.13M | Sales 2025 * | - | Capitalization | 51.64M 37.79M 3.15B |
---|---|---|---|---|---|
Net income 2024 * | -5M -3.66M -305M | Net income 2025 * | - | EV / Sales 2024 * | 184 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
10
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.21% |
Managers | Title | Age | Since |
---|---|---|---|
Corey Giasson
CEO | Chief Executive Officer | 46 | 15/18/15 |
Todd Lahti
DFI | Director of Finance/CFO | 58 | 17/18/17 |
Colin Bletsky
COO | Chief Operating Officer | 49 | 15/18/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Quigley
BRD | Director/Board Member | 50 | 17/19/17 |
Brad Munro
CHM | Chairman | 64 | 15/18/15 |
Corey Giasson
CEO | Chief Executive Officer | 46 | 15/18/15 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+48.43% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MGRO Stock
- MGRO Stock